Global imaging giant admits: 'We may not survive!' What happened?

A $500 million debt burden looms—does 133-year-old Kodak have only three months left? This sounds like an implausible market rumor. Unfortunately, the news comes straight from Eastman Kodak’s Q2 2025 earnings call: 'The company may be unable to sustain long-term operations… We are evaluating all options, including suspending pension payments.' Hardly had the words been spoken before the stock plunged 26%. 01. Deteriorating finances, cash flow dried up On August 11, Kodak released its latest financial results: In Q2, Kodak reported revenue of $263 million, down 1% year-on-year; Gross profit stood at $51 million, down 12%; net loss reached $26 million. Multiple financial indicators worsened sharply: in the same period last year, Kodak posted net income of $26 million—switching from profit to loss. Kodak’s core businesses include advanced materials and chemicals, pharmaceuticals, and some brand licensing revenue. At its peak during the film era, its medical imaging business held promising potential. Yet, pressured by poor performance, Kodak spun off and sold its medical imaging division in 2007 after years of losses. However, rising costs and declining operational profitability caused Kodak to spend nearly $46 million in the first half of the year alone. At quarter-end, Kodak’s cash and cash equivalents totaled just $155 million. In its earnings report, Kodak warned that it currently has no viable financing channels or available liquid funds to repay approximately $500 million (roughly RMB 3.59 billion) in debt coming due soon—a situation raising substantial doubt about the company’s ability to continue as a going concern. Ultimately, Kodak reluctantly plans to suspend pension payments to raise cash for repaying the $500 million debt. These measures have triggered investor distrust, sending Kodak’s share price into a cliff-like decline—closing down 19.91%. How did this century-old imaging titan reach such a precipice? 02. A 'prisoner of the era,' thrice pivoting toward healthcare Founded in 1892, Kodak dominated the global imaging industry throughout the 20th century with its cameras and photographic film. Kodak’s decline coincided almost precisely with the rise of digital cameras and smartphones. In 1975, Kodak invented the world’s first digital camera. Yet it failed to seize the opportunities presented by the digital wave. Management, entrenched in its dominance and lucrative profits from film, delayed transformation—and thus missed the market’s turning point. In 2012, the company filed for bankruptcy protection, while Japanese rivals Sony and Canon had already seized control of the digital market. At the time, Kodak faced 100,000 creditors and carried total debt of $6.75 billion. Nonetheless, facing adversity, Kodak attempted healthcare pivots—at least three times. First foray into healthcare: In 1988, Kodak acquired U.S. pharmaceutical firm Sterling for $5.1 billion. Sterling specialized in diagnostic imaging agents, hormonal products, and cardiovascular drugs. Just four years later, Kodak sold the unit at half its acquisition price—marking a disastrous end to this venture.

Stellantis’ revenue rebounds, yet cash continues to drain

Financial results released on October 28 show that in Q3, the company’s net revenue reached €37.611 billion, up 1% year-on-year, while its net loss attributable to shareholders narrowed to €470 million. However, industrial free cash flow remained negative at €4.009 billion for the quarter, bringing the cumulative outflow for the first three quarters to €4.93 billion. Despite higher revenues and reduced losses, this automotive group—owner of Jeep, Peugeot, Citroën, and other brands—must accelerate cash recovery. The primary source of Q3’s cash pressure was working capital absorption. CFO João Laranjo disclosed that changes in working capital drove a net cash outflow of €2.772 billion for the quarter. Scheduled summer production halts reduced output and shipments compared to Q2; shifts in inventory levels, accounts receivable collection, and supplier settlements collectively weighed on cash flow. The company expects increased shipments and reduced year-end dealer inventories to generate positive cash inflows in Q4. U.S. dealer inventory now has a clear reduction target: from approximately 368,000 units at the end of September to 320,000–350,000 units by year-end. Prior production adjustments have already driven a 6% sequential decline in local dealer inventory—but inventory remains 23% higher than a year ago. Inventory reduction and price discipline must proceed simultaneously. Reducing shipments to distribution channels will dampen short-term revenue; excessive inventory buildup, meanwhile, risks forcing dealers to expand discounts—eroding per-vehicle profitability. Filosa stated that improved net pricing in North America during Q3 contributed positively by €425 million, and the company will continue aligning production with market demand to balance sales volume and profitability.

Eastman Sets a $500 Million Starting Point for 2027 Capital Spending

2 days ago

Eastman Chemical plans $500 million in 2027 capital spending, driven by a $375 million DOE award to expand Kingsport output by 30%, restart U.S. recycling assets, and explore a second methanolysis facility.

www.tokenpost.com

2026-01-30

Eastman Chemical, Kolmar Korea Forge Partnership to Advance Biodegradable Personal Care Solutions

2026-04-06

Eastman Chemical Co (EMN) Shares Drop 3.04% on April 6

2026-04-06

Eastman Chemical Co. Stock Underperforms Monday Compared to Competitors

2026-04-08

Global Amines Market Growth Driven by Arkema, Eastman Chemical in North America and Europe Expansion

2026-04-08

Eastman to Post Q1 Results April 30, Hold Webcast May 1